Northwest Biotherapeutics reports initial positive data in cancer candidate tria Northwest Biotherapeutics provided an initial patient case study, showing signs of tumor necrosis or death and initial tumor regression, from the company's ongoing DCVax-Direct trial for all types of inoperable solid tumors. The company continues collecting data from the trial. The specific case study involves a sarcoma patient with a large tumor mass and multiple inoperable metastatic tumors in the lung. This patient's results suggest both local and systemic effects of the DCVax-Direct treatment, as were seen in the pre-clinical studies. These results were further supported by tumor biopsies taken at the time of the most recent injection, which showed a high rate of tumor necrosis and appearance of T cells infiltrating into the injected tumor. The company is currently conducting a 60-patient Phase I/II trial with DCVax-Direct for all types of inoperable solid tumors.
Northwest Biotherapeutics raises $11.5M through an institutional stock sale Northwest Biotherapeutics announced that the Company has entered into an agreement with a single existing institutional shareholder for the purchase and sale of approximately $11.5M of newly issued shares of the Company's Common Stock at a price of $5.05 per share. H.C. Wainwright & Co., LLC acted as the sole placement agent for the transaction.